News - Biotechnology, idelalisib

Filter

Current filters:

Biotechnologyidelalisib

Popular Filters

Idelalisib may represent promising treatment for stubborn blood cancers

11-03-2014

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma…

BiotechnologyGilead SciencesHematologyidelalisibOncologyResearch

Gilead’s idelalisib shows promise in treating indolent non-Hodgkin lymphomas

Gilead’s idelalisib shows promise in treating indolent non-Hodgkin lymphomas

24-01-2014

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing…

BiotechnologyGilead SciencesidelalisibOncologyResearch

Gilead to stop Ph III Study 116 of idelalisib early on DMC recommendation

10-10-2013

Following a recommendation by an independent Data Monitoring Committee, US HIV/AIDS drug major Gilead…

BiotechnologyGilead SciencesidelalisibOncologyResearch

Gilead files for US approval of iNHL drug candidate

12-09-2013

US biotech major Gilead Sciences (Nasdaq: GILD), best known for its prowess in antivirals (HIV and hepatitis…

BiotechnologyGilead SciencesidelalisibNorth AmericaOncologyRegulation

Positive Ph II results for Gilead's idelalisib in refractory indolent non-Hodgkin's lymphoma

17-06-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) today (June 17) announced encouraging interim results…

BiotechnologyGilead SciencesidelalisibOncologyResearch

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top